Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation
Authors:
- S. K. ArakelyanSAS. K. Arakelyan
- S. L. BlagovSBS. L. Blagov
- S. I. KovryginSKS. I. Kovrygin
- A. A. SemchenkovaASA. A. Semchenkova
- M. S. FadeevaMFM. S. Fadeeva
- D. A. EvseevDED. A. Evseev
- T. Yu. SalimovaTST. Yu. Salimova
- Д. Д. БайдильдинаДБД. Д. Байдильдина
- L. N. ShelikhovaLSL. N. Shelikhova
- M. A. MaschanMMM. A. Maschan
- A. A. MaschanAMA. A. Maschan
Open Access
- 12 May 2023
- journal article
- research article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 104-112
Abstract
Pure red cell aplasia (PRCA) is a rare complication of AB0-incompatible allogeneic hematopoietic stem cell transplantation, which manifests as a partial or complete absence of erythroid lineage in recipients with normal function of other hematopoietic lineages. There is a hypothesis, that lysis of erythroid precursors occurs because of antibody formation by population of residual B-lymphocytes and/or long-lived recipient’s plasma cells, which are capable for proliferation and active expression of the CD38 marker. That is why the invention of the IgG1 monoclonal antibody to CD38 presented as a new potentially effective targeted therapeutic option for patients with refractory PPCA. The article summarize clinical data on daratumumab for the therapy of PRCA in pediatric allogeneic hematopoietic stem cell transplantation recipients. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications.Keywords
This publication has 14 references indexed in Scilit:
- Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemiaBlood Cells, Molecules, and Diseases, 2021
- Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre studyBritish Journal of Haematology, 2021
- Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the questionBone Marrow Transplantation, 2020
- Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumabEuropean Journal of Haematology, 2019
- Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantationBone Marrow Transplantation, 2019
- Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumabAmerican Journal of Hematology, 2019
- Daratumumab for Delayed Red-Cell Engraftment after Allogeneic TransplantationNew England Journal of Medicine, 2018
- Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantationHematology/Oncology and Stem Cell Therapy, 2018
- Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantationContemporary Oncology, 2012
- Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemiaBone Marrow Transplantation, 2002